Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Total Non-Current Liabilities (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Total Non-Current Liabilities for 15 consecutive years, with $694.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 19.66% year-over-year to $694.1 million, compared with a TTM value of $694.1 million through Dec 2025, down 19.66%, and an annual FY2025 reading of $686.4 million, down 18.83% over the prior year.
  • Total Non-Current Liabilities was $694.1 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $686.4 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $863.9 million in Q4 2024 and bottomed at $102.6 million in Q2 2021.
  • Average Total Non-Current Liabilities over 5 years is $400.6 million, with a median of $373.0 million recorded in 2022.
  • The sharpest move saw Total Non-Current Liabilities surged 916.01% in 2021, then decreased 21.94% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $128.9 million in 2021, then soared by 189.35% to $373.1 million in 2022, then increased by 4.22% to $388.8 million in 2023, then soared by 122.16% to $863.9 million in 2024, then fell by 19.66% to $694.1 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for ARWR at $694.1 million in Q4 2025, $686.4 million in Q3 2025, and $666.3 million in Q2 2025.